Advertisement

Topics

JPT Peptide Technologies GmbH Company Profile

23:44 EDT 24th September 2018 | BioPortfolio

NIL

Location

Volmerstrasse 5 (UTZ)
Berlin
12489
Germany

Contact

Phone: 49-30-6392-7878
Fax: 49-30-6392-7888
Email: peptide@jpt.com


News Articles [614 Associated News Articles listed on BioPortfolio]

JPT Peptide Technologies Launches The Human Proteome Peptide Catalog

JPT Peptide Technologies (JPT) announces the launch of The Human Proteome Peptide Catalog, the first and most comprehensive online resource for validated reference peptides in mas...

This Oxford Biotech is Using mRNA to Find New Peptide Drugs

Today, we’re in Oxford, UK, visiting Orbit Discovery. The biotech develops peptide drugs for chronic diseases using mRNA display technologies by linking proteins to their encoding DNA. Mission:...

Breakthrough for Peptide Medication: New Strategy Makes Peptide Active Agents Available Orally

Breakthrough for peptide medication - The “Holy Grail” of peptide chemistry: Making peptide active agents available orally. Peptides, short amino acid chains that control many functions in...

United Technologies Corporation: Aus Carrier und CIAT wird UTC Klimatechnik GmbH

Innerhalb der UTC Klimatechnik GmbH werden die beiden Marken als getrennte Geschäftsbereiche geführt. Die Vertriebsleitung für CIAT hat zum Jahresanfang Reinhard Kern übernommen. Der Kälteanlagen...

Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA

CRANBURY, N.J., June 4, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment ...

Merck taps Italian CRO IRBM for peptide drug development

IRBM and Merck have signed a new agreement in the peptide therapeutics area through which the Italian CRO will identify potential peptide leads for a specific Merck target.

Systec GmbH Introduces its new Business Partner Evidencia GmbH

Research, pharmaceuticals, life sciences and food: many laboratories rely on steam sterilizers or equipment where processes are monitored using pressure and temperature control. Thanks to our collabor...

Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

CRANBURY, N.J., March 26, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatmen...

PubMed Articles [1310 Associated PubMed Articles listed on BioPortfolio]

detection of optically-evoked opioid peptide release.

Though the last decade has seen accelerated advances in techniques and technologies to perturb neuronal circuitry in the brain, we are still poorly equipped to adequately dissect endogenous peptide re...

Accelerated microfluidic native chemical ligation at difficult amino acids toward cyclic peptides.

Cyclic peptide-based therapeutics have a promising growth forecast that justifies the development of microfluidic systems dedicated to their production, in phase with the actual transitioning toward c...

Isolation and identification of a novel algicidal peptide from mackerel muscle hydrolysate.

To help remedy damage from harmful algal blooms, an attempt was made to isolate an algicidal substance previously observed to be present in mackerel muscle hydrolysate. Crude extract was obtained by c...

Editing of DNA Methylation Using dCas9-Peptide Repeat and scFv-TET1 Catalytic Domain Fusions.

DNA methylation, one of the most studied epigenetic modifications, regulates many biological processes. Dysregulation of DNA methylation is implicated in the etiology of several diseases, such as canc...

Novel peptide inhibits inflammation by suppressing of protease activated receptor-2.

We synthesized and investigated the effects of a novel peptide B, RRFSLLRY as a novel PAR-2 antagonist. Peptide B decreased calcium levels in HaCat cells stimulated with trypsin and PAR-2 activator (S...

Clinical Trials [1214 Associated Clinical Trials listed on BioPortfolio]

Combination of Radiation Therapy and Peptide Specific CTL Therapy in Treating Patients With Esophageal Cancer

Immunotherapy is now considered to be one of promising approaches for treating cancer. Radiation therapy has been to be a cornerstone treatment for unresectable advanced esophageal cancer....

Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.

To evaluate the chemical efficacy and safety of intranasally administered peptide T on neurocognitive function in HIV seropositive individuals. Previous studies have shown that treatment ...

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

To evaluate safety and immunogenicity of 2 different HIV-1 peptide candidate vaccines, the UBI HIV-1 MN PND peptide immunogen and the UBI microparticulate monovalent HIV-1 MN branched pept...

Patient-individualized Peptide Vaccination in Combination With Lenalidomide After First Line Therapy of CLL

The aim of this study is to induce a peptide-specific immune response in chronic lymphatic leukaemia (CLL) patients by multi-peptide vaccination with a patient-individualized peptide cockt...

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

- Type: Bioequivalence study in male healthy volunteers, therapeutical indication (erectile disfunction) not studied - Products, dosage, and route of administration: ...

Companies [1985 Associated Companies listed on BioPortfolio]

JPT Peptide Technologies GmbH

NIL

Peptide Resource Page

Welcome to the Peptide Resource Page (PRP). Founded in 2004, the PRP is designed to help researchers and educators navigate through the maze of peptide related websites. Search our pages to find pepti...

Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide rece...

AFFiRiS GmbH

AFFiRiS GmbH develops peptide-based vaccines for the treatment of Alzheimer's disease, atherosclerosis and other diseases that urgently require a medical solution. The company has established plat...

Peptide Solutions

Peptide Solutions LLC is a distribution partner for Iris Biotech GmbH in North America and is recognized as a leading supplier of reagents used in drug discovery, drug delivery an...

More Information about "JPT Peptide Technologies GmbH" on BioPortfolio

We have published hundreds of JPT Peptide Technologies GmbH news stories on BioPortfolio along with dozens of JPT Peptide Technologies GmbH Clinical Trials and PubMed Articles about JPT Peptide Technologies GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of JPT Peptide Technologies GmbH Companies in our database. You can also find out about relevant JPT Peptide Technologies GmbH Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record